Percheron Therapeutics Ltd (ASX: PER) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Percheron Therapeutics Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.
Market Cap
$8.70 million
P/E Ratio
N/A
Dividend Yield
0.00%
Shares Outstanding
1.09 billion
Earnings per share
-0.015
Dividend per share
N/A
Year To Date Return
-11.11%
Earnings Yield
N/A
Franking
-
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Percheron Therapeutics Ltd (ASX: PER)
Latest News
Healthcare Shares
Here's why the Antisense (ASX:ANP) share price is climbing 5% today
Healthcare Shares
Antisense (ASX:ANP) share price accelerates 5% on FDA news
Capital Raising
Antisense Therapeutics (ASX:ANP) share price tumbles 8% amid capital raise
Share Fallers
Here's why the Antisense Therapeutics (ASX:ANP) share price has plummeted 19% on Monday
Healthcare Shares
Why the Antisense (ASX:ANP) share price rocketed 16% today
Share Market News
Why the Antisense (ASX:ANP) share price finished 5% higher today
Healthcare Shares
The Antisense (ASX:ANP) share price is surging 7% today. Here's why
Share Market News
Recent development sends the Antisense (ASX:ANP) share price soaring 45%
PER ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Percheron Therapeutics Ltd
Antisense Therapeutics Ltd. engages in the research and development of novel antisense pharmacceuticals. It operates through the ATL1102, and ATL1103 segments. The ATL1102 segment represents the second generation antisense inhibitor of CD49d, the alpha subunit of very late antigen-four. The ATL1103 segment refers to atesidorsen is an antisense drug designed to block growth hormone receptor expression thereby reducing levels of the hormone insulin. The company was founded on November 13, 2000 and is headquartered in Toorak, Australia.
PER Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 23 Jan 2026 | $0.01 | $0.00 | 0.00% | 922,516 | $0.01 | $0.01 | $0.01 |
| 22 Jan 2026 | $0.01 | $0.00 | 0.00% | 1,835,394 | $0.01 | $0.01 | $0.01 |
| 21 Jan 2026 | $0.01 | $0.00 | 0.00% | 311,111 | $0.01 | $0.01 | $0.01 |
| 19 Jan 2026 | $0.01 | $0.00 | 0.00% | 2,093,724 | $0.01 | $0.01 | $0.01 |
| 16 Jan 2026 | $0.01 | $0.00 | 0.00% | 358,282 | $0.01 | $0.01 | $0.01 |
| 15 Jan 2026 | $0.01 | $0.00 | 0.00% | 44,345 | $0.01 | $0.01 | $0.01 |
| 14 Jan 2026 | $0.01 | $0.00 | 0.00% | 1,378,475 | $0.01 | $0.01 | $0.01 |
| 13 Jan 2026 | $0.01 | $0.00 | 0.00% | 195,328 | $0.01 | $0.01 | $0.01 |
| 12 Jan 2026 | $0.01 | $0.00 | 0.00% | 417,821 | $0.01 | $0.01 | $0.01 |
| 09 Jan 2026 | $0.01 | $0.00 | 0.00% | 45,455 | $0.01 | $0.01 | $0.01 |
| 08 Jan 2026 | $0.01 | $0.00 | 0.00% | 30,000 | $0.01 | $0.01 | $0.01 |
| 06 Jan 2026 | $0.01 | $0.00 | 0.00% | 572,626 | $0.01 | $0.01 | $0.01 |
| 05 Jan 2026 | $0.01 | $0.00 | 0.00% | 557,557 | $0.01 | $0.01 | $0.01 |
| 02 Jan 2026 | $0.01 | $0.00 | 0.00% | 118,034 | $0.01 | $0.01 | $0.01 |
| 31 Dec 2025 | $0.01 | $0.00 | 0.00% | 2,792,496 | $0.01 | $0.01 | $0.01 |
| 30 Dec 2025 | $0.01 | $0.00 | 0.00% | 56,118 | $0.01 | $0.01 | $0.01 |
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 22 Dec 2025 | Ben Price | Buy | 2,000,000 | $17,220 |
On-market trade.
|
| 19 Dec 2025 | James Garner | Buy | 1,000,000 | $8,500 |
On-market trade.
|
| 30 Jun 2025 | James Garner | Buy | 2,500,000 | $24,960 |
On-market trade.
|
| 20 May 2025 | Charmaine Gittleson | Issued | 239,999 | $8,399 |
Issue of options.
|
| 20 May 2025 | James Garner | Issued | 5,000,000 | $175,000 |
Issue of options.
|
| 31 Mar 2025 | Ben Price | Buy | 5,000,000 | $58,121 |
On-market trade.
|
| 28 Mar 2025 | James Garner | Buy | 7,500,000 | $81,870 |
On-market trade.
|
| 18 Mar 2025 | Ben Price | Expiry | 1,000,000 | $10,000 |
Options expired.
|
| 26 Feb 2025 | James Garner | Buy | 39,500,000 | $475,276 |
On-market trade.
|
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Mr Robert William Moses | Non-Executive Director | Oct 2001 |
Mr Moses has more than 40 years of experience in the pharmaceutical/ biotechnology industry. He was formerly Corporate Vice President of CSL Limited. Prior to joining CSL, Mr Moses was Managing Director of commercial law firm Freehills, Chairman and CEO of a NASDAQ listed medical service company, and Corporate Manager of New Business Development at ICI (now Orica). Mr Moses is also the former Non-Executive Chairman of TGR Biosciences Pty Ltd. Mr Moses also spent 17 years in various management roles at the multinational pharmaceutical company Eli Lilly.
|
| Dr Ben Gil Price | Non-Executive Director | Oct 2021 |
Dr Price is an experienced biotech executive and entrepreneur with expertise across clinical asset investment strategy, evaluation, financing and execution. Additional leadership experience includes R&D, Medical, and strategic corporate functions. Between November 2021 and January 2023, he served as Neurobo Pharmaceuticals, President and CEO. Prior to joining Neurobo, Gil was Chief Medical Officer of ProPharma Group, a global industry leader in comprehensive compliance services that span the entire lifecycle of pharmaceuticals, biologics, and devices. Gil was previously responsible for the strategic and tactical management of all business at Drug Safety Solutions. Over the years Gil has served on multiple corporate boards, including public, private and not-for-profit. His recent experience, Rexahn Pharmaceuticals, Inc. (NYSE American: RNN) he served on Compensation, Governance, and Business Development. He is a Member of the Governance Committee.
|
| Dr James Garner | Chief Executive OfficerManaging Director | May 2023 |
Dr Garner brings experience in drug development and commercialization, acquired through regional and global roles in the biotech and pharmaceutical sector. His previous responsibilities have included phase I-IV clinical trials, product registration, reimbursement, and business development. Most recently James served as CEO of Kazia Therapeutics Limited (NASDAQ:KZIA), a clinical stage, oncology-focused company where James rebuilt the organization around a pipeline of novel assets and financing via capital markets and non-dilutive opportunities.
|
| Dr Charmaine Gittleson | Executive ChairmanExecutive Director | Mar 2021 |
Dr Gittleson has international experience as a pharmaceutical physician in pharmaceutical drug development, governance and risk management during her 15-year tenure. Charmaine held the key leadership roles of: Senior Director, Head Safety and Clinical Development (2006-2010) in Melbourne Australia; Vice President Clinical Strategy (2010-2013) and Senior Vice President Clinical Development (2013-2017) in Pennsylvania United States; and Chief Medical Officer in Melbourne from 2017 until her recent retirement from corporate roles in 2020. She is a Member of the Governance Committee.
|
| Ms Deborah Ambrosini | Chief Financial OfficerCompany Secretary | Jun 2024 |
-
|
| Deborah Ambrosini | Chief Financial OfficerCompany Secretary |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| Citicorp Nominees Pty Limited | 75,135,889 | 6.91% |
| Dr James Stuart Garner | 52,500,000 | 4.83% |
| Non Correlated Capital Pty Ltd <Investius Pb Micro Cap A/C> | 50,000,000 | 4.60% |
| Powerhouse Ventures Limited | 46,707,181 | 4.29% |
| Mr Glen Corby Bull | 42,000,000 | 3.86% |
| Mutual Investments Pty Ltd <Mitchell Family A/C> | 35,393,981 | 3.25% |
| BNP Paribas Nominees Pty Ltd <Clearstream> | 26,307,270 | 2.42% |
| Mr Siddhartha Kantichand Dhadha | 19,500,000 | 1.79% |
| Mutual Investments Pty Ltd <The Mitchell Super Fund A/C> | 15,350,000 | 1.41% |
| Mr Dale Anthony Reed | 15,050,000 | 1.38% |
| Jamplat Pty Ltd | 14,999,000 | 1.38% |
| Citycastle Pty Ltd | 12,183,036 | 1.12% |
| Mr Colin William Macleod & Mrs Linda Elizabeth Macleod <Macleod Super Fund A/C> | 10,700,000 | 0.98% |
| Mikado Corporation Pty Ltd <Jfc Superannuation A/C> | 10,000,000 | 0.92% |
| Shah Nominees Pty Ltd | 10,000,000 | 0.92% |
| Shah Nominees Pty Ltd <Louis Carsten Super Fund A/C> | 10,000,000 | 0.92% |
| Finclear Services Pty Ltd <Superhero Securities A/C> | 9,584,204 | 0.88% |
| HSBC Custody Nominees (Australia) Limited A/C 2 | 8,542,111 | 0.80% |
| Mr Robertson Mclennan Mitchell & Mrs Karen Joy Mitchell | 8,455,319 | 0.80% |
| Mrs Margaret Ann Ryan & Mr Micheal Rodney Ryan | 8,000,000 | 0.70% |
